1. A 50-year-old man with a body mass index of 38 reports fatigue and reduced libido. His total testosterone is 290 ng/dL (low-normal), his estradiol is mildly elevated, and his luteinizing hormone (LH) is low-normal. Integrating the effects of obesity on both sex hormone-binding globulin (SHBG) and aromatase, which of the following best explains his laboratory pattern and the most appropriate next diagnostic step?
A) Obesity raises SHBG, which falsely elevates total testosterone; the low LH indicates a primary testicular defect, and a testicular biopsy is the appropriate next step.
B) Obesity has no effect on SHBG or aromatase; the low-normal total testosterone fully excludes hypogonadism, and no further testing is warranted.
C) The mildly elevated estradiol directly stimulates Leydig cell testosterone output, so the total testosterone underestimates true gonadal function; the next step is to start an aromatase inhibitor empirically.
D) Obesity lowers SHBG (reducing the protein-bound fraction and thus lowering total testosterone) while increased adipose aromatase activity raises conversion of testosterone to estradiol, and the elevated estradiol enhances central negative feedback, suppressing LH; because the low SHBG makes total testosterone an unreliable index of androgen status, calculated or measured free (bioavailable) testosterone is the appropriate next step.
E) Obesity raises both SHBG and intratesticular testosterone, so the peripheral total testosterone is falsely low while gonadal function is normal; repeating only the total testosterone is sufficient.
ANSWER: D
Rationale:
Option D is correct. This scenario requires integrating two distinct obesity-related effects. First, obesity and its associated insulin resistance lower SHBG; because roughly 60% to 70% of circulating testosterone is normally SHBG-bound, a fall in SHBG lowers the total testosterone measurement even when bioavailable (free plus albumin-bound) testosterone may be relatively preserved. Second, increased adipose tissue expands aromatase (CYP19A1) activity, raising peripheral conversion of testosterone to estradiol; the resulting elevated estradiol strengthens negative feedback at the hypothalamus and pituitary, suppressing LH and contributing to a functional (often partially reversible) secondary hypogonadism. Because the low SHBG renders total testosterone an unreliable index of androgen status in this patient, the correct next step is to obtain calculated free testosterone (from total testosterone, SHBG, and albumin) or a direct free testosterone assay to determine the true bioavailable androgen level before deciding on therapy. Weight loss, which raises SHBG and reduces aromatization, is also a key intervention.
Option A: Option A is incorrect; obesity lowers rather than raises SHBG, and low-normal LH in this setting reflects estradiol-mediated central feedback, not a primary testicular defect requiring biopsy.
Option B: Option B is incorrect; obesity clearly affects both SHBG (decreased) and aromatase (increased), and a low-normal total testosterone in an obese symptomatic man does not exclude hypogonadism — free testosterone assessment is needed.
Option C: Option C is incorrect; estradiol does not directly stimulate Leydig cell testosterone output, and empiric aromatase inhibitor therapy is not the appropriate first diagnostic step; clarifying bioavailable testosterone comes first.
Option E: Option E is incorrect; obesity lowers SHBG (not raises it) and does not raise intratesticular testosterone; the explanation inverts the SHBG effect and the recommended workup is inadequate.
2. A researcher is designing an androgen-modulating drug intended to shrink the prostate and slow scalp hair loss while preserving muscle mass, bone density, and erythropoiesis. Integrating the tissue distribution of 5 alpha-reductase with the differing roles of testosterone and dihydrotestosterone (DHT), which pharmacological strategy best achieves this selective profile, and why?
A) A pure androgen receptor antagonist (e.g., bicalutamide), because blocking the androgen receptor in all tissues simultaneously reduces prostate growth while sparing muscle and bone through an unexplained tissue-protective effect.
B) A 5 alpha-reductase inhibitor (e.g., finasteride), because DHT — produced locally by 5 alpha-reductase and the dominant androgen in the prostate, scalp, and skin — drives growth in those tissues, whereas muscle protein synthesis, bone maintenance, and erythropoiesis are mediated predominantly by testosterone itself; inhibiting 5 alpha-reductase lowers DHT in DHT-dependent tissues while leaving testosterone-mediated effects largely intact.
C) An aromatase inhibitor (e.g., anastrozole), because blocking conversion of testosterone to estradiol raises testosterone in all tissues, selectively shrinking the prostate while building muscle.
D) A GnRH agonist, because suppressing luteinizing hormone lowers testosterone production globally, which selectively reduces prostate size without affecting muscle, bone, or red cell mass.
E) Supraphysiological exogenous testosterone, because saturating the androgen receptor in muscle while down-regulating prostate receptors selectively reduces prostate volume.
ANSWER: B
Rationale:
Option B is correct. The selective profile described — reduce prostate and scalp androgenic stimulation while preserving muscle, bone, and erythropoiesis — maps directly onto the pharmacology of 5 alpha-reductase inhibition. DHT is produced locally from testosterone by 5 alpha-reductase (predominantly the type 2 isoform in prostate and scalp), binds the androgen receptor with higher affinity than testosterone, and is the dominant androgen driving prostate growth, male-pattern hair loss, and sebaceous activity. In contrast, the anabolic effects on skeletal muscle, the maintenance of bone (partly via aromatization to estradiol), and erythropoiesis are mediated predominantly by testosterone itself, not by DHT. Therefore, a 5 alpha-reductase inhibitor lowers DHT selectively in DHT-dependent tissues while leaving circulating testosterone (and its muscle, bone, and erythropoietic effects) largely intact — exactly the desired tissue-selective profile.
Option A: Option A is incorrect; a pure androgen receptor antagonist blocks the receptor in all tissues including muscle and bone, so it would not spare those tissues — there is no tissue-protective mechanism that exempts muscle and bone from systemic AR blockade.
Option C: Option C is incorrect; an aromatase inhibitor raises testosterone and lowers estradiol, which would not selectively shrink the prostate and would risk bone loss from estradiol deficiency.
Option D: Option D is incorrect; a GnRH agonist suppresses testosterone globally, producing exactly the muscle, bone, and erythropoietic losses the design seeks to avoid.
Option E: Option E is incorrect; supraphysiological testosterone would increase substrate for intraprostatic DHT production and stimulate, not reduce, prostate growth; the proposed selective receptor down-regulation mechanism is not how androgen pharmacology operates.
3. A man with metastatic prostate cancer is treated with bicalutamide monotherapy. After several weeks his serum testosterone has risen above baseline, and his prostate-specific antigen (PSA) decline is incomplete. Integrating the feedback consequences of androgen receptor blockade with the rationale for combined androgen blockade, which of the following best explains this result and the appropriate adjustment?
A) Bicalutamide has lost potency because of rapid hepatic autoinduction; the appropriate adjustment is simply to double the bicalutamide dose, which restores complete androgen receptor blockade without other therapy.
B) The rising testosterone reflects adrenal androgen overproduction that bypasses the testes; the appropriate adjustment is a corticosteroid to suppress the adrenal axis, with no need to address testicular testosterone.
C) The incomplete PSA decline indicates AR-V7-mediated resistance from the outset; the appropriate adjustment is immediate taxane chemotherapy without any hormonal manipulation.
D) The rising testosterone proves the tumor is hormone-independent; the appropriate adjustment is to discontinue all androgen-directed therapy.
E) Because bicalutamide blocks the androgen receptor at the hypothalamus and pituitary without progestogenic activity, it removes testosterone negative feedback, raising LH and driving testicular testosterone approximately 1.5-fold above baseline; this elevated testosterone partially competes with bicalutamide at the receptor in tumor tissue, explaining the incomplete response. Adding a GnRH agonist or antagonist (or orchiectomy) to suppress testicular testosterone achieves combined androgen blockade and eliminates the testosterone escape.
ANSWER: E
Rationale:
Option E is correct. This question integrates the feedback physiology of androgen receptor (AR) blockade with the therapeutic rationale for combined androgen blockade (CAB). Bicalutamide is a non-steroidal AR antagonist without progestogenic activity, so it does not suppress gonadotropin secretion. When it blocks the AR at the hypothalamus and pituitary, it removes testosterone's negative feedback, causing LH to rise and testicular testosterone to climb to roughly 1.5 times baseline. This elevated circulating testosterone competes with bicalutamide for AR binding in peripheral tissues, including the tumor, which limits the completeness of androgen blockade and explains the blunted PSA response during monotherapy. The pharmacologically correct adjustment is to suppress testicular testosterone production by adding a GnRH agonist or antagonist (or by surgical orchiectomy), achieving combined androgen blockade and removing the testosterone escape.
Option A: Option A is incorrect; the rising testosterone is not due to hepatic autoinduction of bicalutamide metabolism, and dose-doubling does not address the underlying testosterone escape driven by loss of negative feedback.
Option B: Option B is incorrect; the testosterone rise is testicular (LH-driven), not adrenal, so corticosteroid adrenal suppression does not address the mechanism.
Option C: Option C is incorrect; an incomplete early PSA decline during bicalutamide monotherapy is explained by the testosterone-escape mechanism, not necessarily by AR-V7 resistance, and proceeding directly to taxane without first achieving castration-level testosterone suppression is not the appropriate next step at this stage.
Option D: Option D is incorrect; the rising testosterone reflects an expected feedback consequence of AR blockade, not proof of hormone independence; androgen-directed therapy should be intensified (CAB), not abandoned.
4. A man with metastatic prostate cancer involving the vertebral column is about to begin a GnRH agonist (leuprolide). His oncologist starts bicalutamide several days before the leuprolide injection and continues it for the first few weeks. Integrating the mechanism of GnRH agonist action with the rationale for this co-administration, which of the following best explains the strategy?
A) GnRH agonists initially stimulate the pituitary, producing a transient surge in LH and a corresponding rise in testosterone (the "flare") during the first one to two weeks before receptor downregulation produces sustained suppression; in a patient with vertebral metastases, this testosterone surge could transiently stimulate tumor growth and precipitate spinal cord compression. Bicalutamide is given before and during the flare to block the androgen receptor and protect against the clinical consequences of the surge until the GnRH agonist achieves castrate testosterone levels.
B) GnRH agonists immediately and permanently suppress LH with no initial surge; bicalutamide is added only to treat pre-existing gynecomastia and has no role in flare protection.
C) Bicalutamide accelerates the onset of GnRH agonist action by enhancing pituitary downregulation, shortening the time to castrate testosterone; it provides no independent receptor-level protection.
D) The bicalutamide is given to prevent the hypotension that GnRH agonists characteristically cause during the first week of therapy; it has no relationship to testosterone dynamics.
E) GnRH agonists cause an initial profound drop in testosterone followed by a rebound surge after several months; bicalutamide is timed to block this late rebound rather than any early effect.
ANSWER: A
Rationale:
Option A is correct. This question integrates the biphasic mechanism of GnRH agonists with the clinical rationale for flare protection. When a GnRH agonist such as leuprolide is first administered, it initially stimulates pituitary GnRH receptors, producing a transient surge in LH (and FSH) and a corresponding rise in testosterone — the "testosterone flare" — over roughly the first one to two weeks. Only after sustained receptor occupancy downregulates and desensitizes the pituitary gonadotrophs does testosterone fall to castrate levels. In a patient with vertebral (spinal) metastases, the testosterone flare can transiently stimulate tumor growth and precipitate serious complications such as spinal cord compression, ureteral obstruction, or bone pain. Co-administering bicalutamide — a non-steroidal androgen receptor antagonist — beginning before and continuing during the flare period blocks the androgen receptor in tumor tissue, protecting against the clinical consequences of the surge until the GnRH agonist achieves and maintains castrate testosterone.
Option B: Option B is incorrect; GnRH agonists do produce an initial testosterone surge (they do not immediately and permanently suppress LH), and bicalutamide's role here is flare protection, not gynecomastia treatment.
Option C: Option C is incorrect; bicalutamide does not accelerate pituitary downregulation; it provides independent receptor-level blockade during the flare.
Option D: Option D is incorrect; GnRH agonists do not characteristically cause hypotension in the first week, and bicalutamide's role is tied directly to testosterone dynamics.
Option E: Option E is incorrect; the clinically important surge is the early flare (first one to two weeks), not a late rebound after months; bicalutamide is timed to the early surge.
5. A hypogonadal man on testosterone replacement develops gynecomastia, and his physician considers adding an aromatase inhibitor to lower estradiol. Integrating the role of estradiol in male physiology with the consequences of aromatase inhibition, which of the following best describes the principal risk of aggressively suppressing estradiol in this man?
A) Suppressing estradiol will raise SHBG to dangerous levels, abolishing all bioavailable testosterone and producing acute androgen deficiency despite ongoing testosterone therapy.
B) Suppressing estradiol has no physiological downside in men because estradiol serves no essential function in male tissues; the only effect is resolution of gynecomastia.
C) In men, approximately 80% of circulating estradiol arises from peripheral aromatization of testosterone, and this estradiol is essential for maintaining bone mineral density (via estrogen receptor-mediated effects in bone). Aggressive aromatase inhibition can therefore reduce bone mineral density and increase fracture risk over time, in addition to potentially impairing libido — so estradiol should be lowered judiciously, not maximally suppressed.
D) Suppressing estradiol will immediately convert the administered testosterone into dihydrotestosterone, causing acute prostate enlargement and urinary retention as the principal risk.
E) Suppressing estradiol eliminates negative feedback on the pituitary, causing a surge of LH that overstimulates the testes and produces testicular rupture as the principal risk.
ANSWER: C
Rationale:
Option C is correct. This question integrates the physiological role of estradiol in men with the downstream consequences of pharmacologic aromatase inhibition. In men, roughly 80% of circulating estradiol is derived from peripheral aromatization of testosterone (and androstenedione) by aromatase (CYP19A1) in adipose and other tissues. This estradiol is not a vestigial byproduct — it is essential for maintaining bone mineral density through estrogen receptor-mediated effects in osteoblasts and for epiphyseal growth plate closure, and it contributes to libido and gonadotropin feedback. Consequently, aggressive aromatase inhibition to abolish estradiol can reduce bone mineral density and increase long-term fracture risk, and may impair libido. The clinical principle is that when gynecomastia prompts consideration of an aromatase inhibitor, estradiol should be lowered judiciously to a physiologic range rather than maximally suppressed.
Option A: Option A is incorrect; aromatase inhibition does not raise SHBG to a degree that abolishes bioavailable testosterone; this is not the mechanism of concern.
Option B: Option B is incorrect; estradiol has essential physiological functions in men (notably bone maintenance), so suppressing it is not without downside.
Option D: Option D is incorrect; blocking aromatase does not divert testosterone into DHT via a forced conversion; 5 alpha-reductase activity is independent, and acute prostate enlargement with retention is not the characteristic risk of aromatase inhibition.
Option E: Option E is incorrect; while reduced estradiol can modestly raise LH by reducing feedback, this does not cause testicular rupture; the framed catastrophic outcome is not a real pharmacological consequence.
6. Two hypogonadal men receive androgen-axis therapy. Man 1 receives exogenous testosterone gel; Man 2 receives human chorionic gonadotropin (hCG). After 6 months, Man 1 is azoospermic while Man 2 maintains sperm production. Integrating the relationship between intratesticular testosterone and spermatogenesis with the differing mechanisms of these two therapies, which of the following best explains the divergent fertility outcomes?
A) Exogenous testosterone gel is absorbed into the testis and directly poisons germ cells, whereas hCG is excluded from the testis and therefore spares spermatogenesis.
B) Spermatogenesis requires intratesticular testosterone at concentrations far above serum levels, maintained by LH-driven Leydig cell stimulation. Exogenous testosterone suppresses hypothalamic GnRH and pituitary LH/FSH, collapsing intratesticular testosterone despite adequate serum testosterone — producing azoospermia. hCG, by acting as an LH-receptor agonist directly on Leydig cells, maintains high intratesticular testosterone (and, with FSH activity preserved or supplemented, Sertoli cell support), thereby preserving spermatogenesis.
C) Exogenous testosterone raises FSH while suppressing LH, and the high FSH alone destroys germ cells; hCG lowers FSH and therefore protects them.
D) hCG suppresses the pituitary more completely than exogenous testosterone, and this deeper suppression paradoxically preserves spermatogenesis through a rebound mechanism.
E) Both therapies suppress intratesticular testosterone equally; Man 2's preserved fertility is unrelated to hCG and reflects only individual variation.
ANSWER: B
Rationale:
Option B is correct. This question integrates the concept that spermatogenesis depends on intratesticular testosterone — maintained at roughly 50 to 100 times serum concentrations by LH-driven Leydig cell stimulation — with the contrasting mechanisms of exogenous testosterone and hCG. Exogenous testosterone (Man 1) raises serum testosterone but suppresses hypothalamic GnRH and pituitary LH and FSH through negative feedback; the loss of LH drive collapses intratesticular testosterone far below the threshold required for spermatogenesis, and FSH suppression removes Sertoli cell support, producing oligospermia or azoospermia despite adequate serum testosterone. hCG (Man 2) is an LH-receptor agonist that acts directly on Leydig cells to sustain high intratesticular testosterone without suppressing the axis the way exogenous testosterone does; when FSH activity is preserved or supplemented, Sertoli cell support is maintained, and spermatogenesis continues. The divergent outcomes therefore follow directly from what happens to intratesticular testosterone under each therapy.
Option A: Option A is incorrect; exogenous testosterone does not directly poison germ cells, and hCG is not excluded from the testis; the mechanism is feedback suppression of intratesticular testosterone versus its maintenance.
Option C: Option C is incorrect; exogenous testosterone suppresses FSH (it does not raise it), and high FSH does not destroy germ cells — FSH supports spermatogenesis.
Option D: Option D is incorrect; hCG does not suppress the pituitary more completely; it bypasses the pituitary by acting directly at the LH receptor, and there is no rebound mechanism involved.
Option E: Option E is incorrect; the two therapies do not suppress intratesticular testosterone equally — that is precisely the difference — and Man 2's preserved fertility is a direct pharmacological consequence of hCG, not random variation.
7. A man has been on finasteride 5 mg daily for BPH for 2 years. His PSA, which had stabilized at a low value after the expected reduction, has now risen steadily over the past 6 months from 1.2 to 2.4 ng/mL while he remains adherent. Integrating the pharmacodynamic effect of finasteride on PSA with the principles of cancer surveillance over time, which of the following is the most appropriate interpretation?
A) The rise is fully explained by finasteride wearing off; the appropriate response is to increase the finasteride dose to re-suppress the PSA and continue routine screening.
B) Because finasteride halves PSA, the true value is only about 1.2 ng/mL; the measured rise is an artifact of the correction factor and requires no further action.
C) A rising PSA on finasteride simply reflects normal prostate growth despite therapy and carries no concern as long as the absolute value stays below 4 ng/mL.
D) After the initial finasteride-induced PSA reduction (roughly 50%) has stabilized, any subsequent sustained rise in PSA during continued therapy should be treated as a potential warning sign for prostate cancer and prompt evaluation — regardless of the absolute value — because the drug's suppressive effect should keep PSA low; the doubling correction is applied to interpret absolute values, but a rising trend on stable therapy is itself the alarm. This patient warrants urologic evaluation.
E) The rise should be ignored because finasteride makes PSA uninterpretable; PSA should no longer be followed in any man on a 5 alpha-reductase inhibitor.
ANSWER: D
Rationale:
Option D is correct. This question integrates finasteride's pharmacodynamic effect on PSA with longitudinal cancer surveillance. Finasteride reduces PSA by approximately 50% within the first 3 to 6 months by suppressing DHT-driven PSA transcription; after this reduction the PSA stabilizes at a new lower baseline. Two interpretive principles then apply. First, to interpret an absolute value, the measured PSA is doubled to estimate the equivalent untreated value. Second — and critical here — any sustained upward trend in PSA during continued, adherent 5 alpha-reductase inhibitor therapy is itself a warning sign, because the drug's ongoing suppressive effect should keep PSA low; a steadily rising PSA on stable therapy should not occur from BPH alone and should prompt evaluation for prostate cancer regardless of whether the absolute value remains below a nominal threshold. This patient's PSA has doubled over 6 months on stable finasteride and warrants urologic evaluation.
Option A: Option A is incorrect; finasteride does not "wear off" in an adherent patient, and dose escalation to mask a rising PSA would be dangerous, potentially delaying cancer diagnosis.
Option B: Option B is incorrect; the correction factor is for interpreting absolute values, not for dismissing a rising trend — the trend itself is the alarm.
Option C: Option C is incorrect; a rising PSA on a 5 alpha-reductase inhibitor is not benign prostate growth, and reassurance based solely on staying under 4 ng/mL ignores the suppressive pharmacodynamics that should keep the value low.
Option E: Option E is incorrect; PSA remains interpretable and useful in men on 5 alpha-reductase inhibitors when the correction factor and trend principles are applied; it should continue to be followed, not abandoned.
8. A pharmacology student is asked to explain why modern oral testosterone undecanoate can be given orally without the hepatotoxicity that plagued older oral agents such as methyltestosterone. Integrating the absorption route of testosterone undecanoate with the structural basis of methyltestosterone's hepatotoxicity, which of the following is the correct explanation?
A) Oral testosterone undecanoate is absorbed via the intestinal lymphatics (through chylomicron incorporation, which is why it must be taken with dietary fat), bypassing hepatic first-pass metabolism and avoiding the need for 17-alpha-alkylation; methyltestosterone, by contrast, required a 17-alpha-methyl group to survive hepatic first-pass when absorbed via the portal route, and that same alkylation impaired hepatic conjugation and excretion, producing cholestasis and other hepatotoxicity. The difference in hepatotoxicity therefore traces to absorption route and the presence or absence of 17-alpha-alkylation.
B) Both agents are absorbed identically through the portal vein; testosterone undecanoate simply contains a hepatoprotective additive that neutralizes the toxicity of 17-alpha-alkylation.
C) Testosterone undecanoate is 17-alpha-alkylated like methyltestosterone but at a lower dose, so its hepatotoxicity is merely less pronounced rather than mechanistically avoided.
D) Methyltestosterone was non-hepatotoxic; the modern reformulation as undecanoate was undertaken solely to extend half-life, with no relationship to liver safety.
E) Oral testosterone undecanoate avoids hepatotoxicity because it is a prodrug activated only in the kidney, completely bypassing the liver at all stages of metabolism.
ANSWER: A
Rationale:
Option A is correct. This question integrates the absorption pharmacology of oral testosterone undecanoate with the structural basis of older oral androgen hepatotoxicity. Testosterone undecanoate's long fatty-acid ester chain makes it lipophilic enough to be incorporated into chylomicrons in enterocytes and absorbed into the intestinal lymphatics (thoracic duct), entering the systemic circulation while bypassing hepatic first-pass metabolism — which is also why it must be taken with a fat-containing meal to drive chylomicron formation. Because it avoids the portal-hepatic first pass, it does not require the 17-alpha-alkyl modification that older oral agents needed. Methyltestosterone and similar early oral androgens were absorbed via the portal route and required a 17-alpha-methyl group to resist hepatic oxidation at the 17-beta hydroxyl; that same alkylation impaired hepatocyte conjugation and biliary excretion, producing intrahepatic cholestasis, peliosis hepatis, and tumor risk. So the hepatotoxicity difference traces to two integrated factors: absorption route (lymphatic vs portal) and the presence or absence of 17-alpha-alkylation.
Option B: Option B is incorrect; the two agents are not absorbed identically, and there is no hepatoprotective additive — the difference is mechanistic (route and structure).
Option C: Option C is incorrect; testosterone undecanoate is not 17-alpha-alkylated; it is a 17-beta ester, so its hepatic safety is mechanistic, not merely a dose effect.
Option D: Option D is incorrect; methyltestosterone is hepatotoxic, and the reformulation relates directly to avoiding that toxicity, not solely to half-life.
Option E: Option E is incorrect; testosterone undecanoate is not activated in the kidney; it is cleaved by serum esterases after lymphatic absorption, and the liver is bypassed at first pass, not at all stages.
9. A 58-year-old man on biweekly intramuscular testosterone cypionate has developed recurrent erythrocytosis requiring repeated phlebotomy, and he has a history of prior deep vein thrombosis. Integrating the mechanism linking testosterone formulation to erythrocytosis and thrombotic risk, which adjustment is most rational, and why?
A) Switch to a higher-dose, less frequent intramuscular injection (e.g., testosterone undecanoate every 10 weeks at a larger dose), because less frequent dosing reduces the cumulative testosterone exposure responsible for erythrocytosis.
B) Discontinue all testosterone therapy permanently and provide no alternative, because any androgen exposure in a man with prior thrombosis is absolutely contraindicated and no formulation can be used.
C) Add an aromatase inhibitor, because converting more testosterone to estradiol is what drives erythrocytosis, and blocking aromatase will resolve the elevated hematocrit.
D) Continue the same biweekly injectable regimen but simply increase the phlebotomy frequency indefinitely, since formulation choice has no bearing on the degree of erythrocytosis.
E) Switch from the biweekly injectable to a transdermal formulation (gel or patch), because injectable esters produce supraphysiological peaks that drive greater erythrocytosis than transdermal preparations, which deliver lower, steadier testosterone levels; reducing the erythrocytogenic stimulus lowers hematocrit, blood viscosity, and the associated thrombotic risk — particularly important given his prior venous thromboembolism.
ANSWER: E
Rationale:
Option E is correct. This question integrates the formulation-dependent pharmacokinetics of testosterone with the erythrocytosis-viscosity-thrombosis chain. Injectable testosterone esters, especially on a biweekly schedule, produce supraphysiological peak concentrations that drive erythropoiesis more strongly than transdermal preparations; the resulting erythrocytosis raises hematocrit, increases whole-blood viscosity, and elevates thrombotic risk. In a man with recurrent erythrocytosis and a prior deep vein thrombosis, the most rational adjustment is to switch to a transdermal gel or patch, which delivers lower and steadier serum testosterone, reducing the erythrocytogenic stimulus and thereby lowering hematocrit and viscosity-related thrombotic risk (alongside continued hematocrit monitoring and dose titration).
Option A: Option A is incorrect; switching to a higher-dose, longer-interval injectable would not reliably reduce erythrocytosis and could worsen the supraphysiological-peak problem; less frequent dosing at higher dose does not lower cumulative erythrocytogenic exposure in the needed way.
Option B: Option B is incorrect; a prior thrombosis does not make all testosterone therapy absolutely contraindicated, and abandoning therapy without considering a safer formulation is not the most rational step.
Option C: Option C is incorrect; erythrocytosis is driven by testosterone's direct erythroid stimulation, hepcidin suppression, and erythropoietin effects — not by conversion to estradiol — so an aromatase inhibitor does not address the mechanism.
Option D: Option D is incorrect; formulation choice does affect the degree of erythrocytosis, so simply escalating phlebotomy while ignoring the driver is inferior to changing to a steadier-delivery formulation.
10. A man with castration-resistant prostate cancer progresses on enzalutamide. Circulating tumor cell testing returns AR-V7 positive. His oncologist explains that switching to a different androgen receptor-directed agent (e.g., abiraterone or a newer AR antagonist) is unlikely to help, but taxane chemotherapy may. Integrating the molecular basis of AR-V7 with the mechanisms of these therapeutic classes, which of the following best explains this reasoning?
A) AR-V7 is a gain-of-function mutation in the ligand-binding domain that binds all AR antagonists with higher affinity; taxanes work because they bind the same ligand-binding domain even more tightly and outcompete the variant.
B) AR-V7 increases dependence on circulating androgens, so switching to abiraterone (which lowers androgen synthesis) is actually the preferred next step, and taxanes are reserved only for AR-V7-negative disease.
C) AR-V7 is a constitutively active AR splice variant that lacks the ligand-binding domain, so it signals without androgen and cannot be blocked by agents that act at that domain or that lower ligand availability (AR antagonists and abiraterone alike rely on the ligand-binding domain or on androgen depletion). Taxanes act on microtubules — a mechanism entirely independent of the AR and its splice variants — and therefore retain activity against AR-V7-positive disease.
D) AR-V7 silences the AR entirely, making the tumor androgen-independent through loss of all AR signaling; taxanes work simply because the tumor has become hormonally inert.
E) AR-V7 is a transporter that pumps AR antagonists out of the cell; taxanes work because they inhibit this efflux pump, restoring antagonist sensitivity.
ANSWER: C
Rationale:
Option C is correct. This question integrates the molecular nature of AR-V7 with the mechanisms of competing therapeutic classes to justify treatment sequencing. AR-V7 is a constitutively active, truncated androgen receptor splice variant that lacks the C-terminal ligand-binding domain (LBD); it activates androgen-responsive transcription without any androgen ligand. Two consequences follow. First, competitive AR antagonists (enzalutamide, apalutamide, darolutamide, bicalutamide) bind the LBD, so a receptor lacking the LBD cannot be blocked by them. Second, abiraterone works by inhibiting CYP17A1 to lower androgen synthesis — but a receptor that does not need ligand is not meaningfully suppressed by depriving it of ligand. Thus both ligand-binding-dependent and ligand-depletion strategies are predicted to fail in AR-V7-positive disease. Taxanes (docetaxel, cabazitaxel), by contrast, act on microtubules to disrupt mitotic spindle function and intracellular trafficking — a mechanism wholly independent of the AR or its splice variants — and therefore retain activity regardless of AR-V7 status.
Option A: Option A is incorrect; AR-V7 lacks the LBD (it is not a higher-affinity LBD mutation), and taxanes do not act at the LBD at all.
Option B: Option B is incorrect; AR-V7 reduces, not increases, dependence on circulating androgens (it is ligand-independent), so abiraterone is not the preferred next step, and taxanes are indicated in AR-V7-positive disease.
Option D: Option D is incorrect; AR-V7 does not silence the AR; it is constitutively active (gain of androgen-independent signaling), not loss-of-function.
Option E: Option E is incorrect; AR-V7 is a transcription factor variant, not a drug efflux transporter, and taxanes do not act by inhibiting efflux pumps.
11. A 30-year-old woman with PCOS and hirsutism is started on spironolactone 150 mg daily. She also takes an ACE inhibitor for hypertension and a potassium supplement prescribed elsewhere. Integrating spironolactone's dual receptor activity with this medication context, which of the following best captures both the therapeutic benefit and the principal safety concern?
A) Spironolactone helps hirsutism purely through diuresis-induced weight loss; its only safety concern is dehydration, and the concurrent ACE inhibitor and potassium supplement are irrelevant.
B) Spironolactone benefits hirsutism through anti-androgenic activity (androgen receptor blockade plus reduced adrenal androgen synthesis), but it is simultaneously a mineralocorticoid receptor antagonist that reduces renal potassium excretion; combined with an ACE inhibitor (which lowers aldosterone) and an exogenous potassium supplement, the additive effects substantially raise the risk of hyperkalemia, so potassium must be monitored and the supplement reconsidered.
C) Spironolactone lowers potassium by acting as a loop diuretic, so combining it with an ACE inhibitor and potassium supplement is protective against hypokalemia and carries no hyperkalemia risk.
D) Spironolactone's anti-androgenic benefit comes from stimulating the androgen receptor, and its principal safety concern is hypernatremia rather than any potassium disturbance.
E) Spironolactone has no interaction with the renin-angiotensin-aldosterone system and no effect on potassium; the combination with an ACE inhibitor and potassium supplement is pharmacologically inert.
ANSWER: B
Rationale:
Option B is correct. This question integrates spironolactone's dual receptor pharmacology with a real-world medication context. Therapeutically, at the 100 to 200 mg/day doses used for hirsutism and PCOS, spironolactone exerts anti-androgenic effects through competitive androgen receptor blockade and reduced adrenal androgen synthesis (CYP17A1 inhibition at higher doses), which is what improves hirsutism. Simultaneously, spironolactone is a mineralocorticoid receptor (MR) antagonist; by blocking aldosterone at the distal nephron it reduces renal potassium excretion, predisposing to hyperkalemia. The safety concern is compounded here because the patient also takes an ACE inhibitor (which lowers aldosterone and thereby further reduces potassium excretion) and an exogenous potassium supplement; these effects are additive, substantially raising hyperkalemia risk. The correct clinical response is to monitor serum potassium and reconsider the potassium supplement and the overall combination.
Option A: Option A is incorrect; spironolactone's benefit in hirsutism is anti-androgenic, not from diuresis-induced weight loss, and the concurrent ACE inhibitor and potassium supplement are highly relevant to hyperkalemia risk.
Option C: Option C is incorrect; spironolactone is a potassium-sparing agent (MR antagonist), not a loop diuretic, so it raises rather than lowers potassium, and the combination increases hyperkalemia risk.
Option D: Option D is incorrect; spironolactone blocks (does not stimulate) the androgen receptor, and its principal electrolyte concern is hyperkalemia, not hypernatremia.
Option E: Option E is incorrect; spironolactone acts directly on the mineralocorticoid receptor within the renin-angiotensin-aldosterone system and clearly affects potassium handling, so the combination is far from inert.
12. A 26-year-old man who completed a high-dose anabolic-androgenic steroid (AAS) cycle now has testicular atrophy, low LH, low FSH, and azoospermia. He wants to recover endogenous testosterone production and fertility. Integrating the mechanism of AAS-induced suppression with the pharmacology of recovery agents, which approach is most rational?
A) Administer high-dose exogenous testosterone indefinitely, because supplying testosterone will signal the testes to resume their own production through positive feedback.
B) Administer a GnRH antagonist, because further blocking the hypothalamic-pituitary axis will trigger a compensatory rebound in endogenous gonadotropin secretion.
C) Administer an aromatase inhibitor alone as the definitive therapy, because the entire suppression is caused by excess estradiol and removing it fully restores spermatogenesis without any other agent.
D) Recognize that exogenous AAS suppressed the hypothalamic-pituitary-gonadal axis via negative feedback (reducing GnRH, LH, and FSH and collapsing intratesticular testosterone), then use recovery pharmacology that restores the axis: human chorionic gonadotropin (hCG) to provide LH-receptor stimulation and restore intratesticular testosterone, and a selective estrogen receptor modulator (SERM) such as clomiphene to block hypothalamic estrogen feedback and raise endogenous LH and FSH — thereby driving recovery of testosterone production and spermatogenesis.
E) Do nothing pharmacologically and simply wait, because AAS-induced azoospermia is permanent and irreversible in all users, making any intervention futile.
ANSWER: D
Rationale:
Option D is correct. This question integrates the mechanism of AAS-induced suppression with the pharmacology of recovery agents. Exogenous AAS suppress the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback, lowering GnRH pulsatility and pituitary LH and FSH secretion; the loss of LH drive collapses intratesticular testosterone (producing testicular atrophy and azoospermia). Rational recovery therefore aims to restart the axis. Human chorionic gonadotropin (hCG) acts as an LH-receptor agonist on Leydig cells to directly restore intratesticular testosterone, and a selective estrogen receptor modulator (SERM) such as clomiphene blocks hypothalamic estrogen receptor feedback to raise endogenous LH and FSH, stimulating the patient's own testosterone production and spermatogenesis. These agents are used (sometimes together, often sequentially) to drive HPG axis and fertility recovery after AAS cessation.
Option A: Option A is incorrect; exogenous testosterone acts through negative (not positive) feedback and would further suppress the axis, worsening the suppression it is meant to reverse.
Option B: Option B is incorrect; a GnRH antagonist would deepen axis suppression, not trigger a beneficial rebound.
Option C: Option C is incorrect; AAS suppression is driven primarily by androgen (and to a lesser extent estrogen) negative feedback on the HPG axis, not solely by excess estradiol, so an aromatase inhibitor alone is not the definitive restorative therapy.
Option E: Option E is incorrect; AAS-induced azoospermia is frequently reversible over 6 to 24 months, often aided by recovery pharmacology, and is not uniformly permanent — so intervention is not futile.
13. A medicinal chemist claims to have designed an oral anabolic steroid that is "purely anabolic with no androgenic effects and no liver toxicity." Integrating the shared receptor basis of anabolic and androgenic effects with the structural requirements for oral activity, which of the following best explains why this claim is implausible?
A) Both anabolic effects (muscle protein synthesis, erythropoiesis) and androgenic effects (prostate growth, virilization) are mediated through the same androgen receptor, so no currently available agent fully dissociates the two — structural modifications shift the ratio but do not eliminate androgenic activity. Moreover, conferring oral activity on a steroid has historically required 17-alpha-alkylation, which is precisely the modification that impairs hepatic conjugation and excretion and produces hepatotoxicity; so an orally active, 17-alpha-alkylated anabolic agent that is simultaneously free of androgenic effects and hepatotoxicity is not consistent with known androgen pharmacology.
B) Anabolic and androgenic effects are mediated by two entirely separate receptors, so complete dissociation is routine; the only barrier is regulatory approval, not pharmacology.
C) Oral activity can be conferred without any structural modification, so 17-alpha-alkylation and its hepatotoxicity are irrelevant to the claim, which is therefore plausible.
D) Androgenic effects are mediated by estrogen receptors and anabolic effects by androgen receptors, so blocking aromatase fully separates the two and the claim is entirely achievable.
E) Hepatotoxicity of oral steroids arises from renal rather than hepatic metabolism, so an agent that bypasses the kidney would be both orally active and non-toxic, validating the claim.
ANSWER: A
Rationale:
Option A is correct. This question integrates two concepts: the shared receptor basis of anabolic and androgenic effects, and the structural requirement for oral activity. Both the anabolic effects (skeletal muscle protein synthesis, bone density, erythropoiesis) and the androgenic effects (prostate growth, sebaceous stimulation, virilization) are mediated through the same androgen receptor; consequently, no currently available anabolic-androgenic steroid achieves complete dissociation of anabolic from androgenic activity — structural modifications can shift the anabolic-to-androgenic ratio but cannot abolish androgenic activity, because the same receptor transduces both. Separately, conferring oral bioavailability on a steroid has historically required 17-alpha-alkylation to resist hepatic first-pass oxidation, and that very modification impairs hepatocyte conjugation and biliary excretion, producing the characteristic hepatotoxicity of oral AAS. An agent that is orally active, purely anabolic, and free of hepatotoxicity would therefore have to violate both established principles simultaneously, which is why the chemist's claim is implausible within known androgen pharmacology. (Newer non-steroidal selective androgen receptor modulators aim to improve tissue selectivity, but a complete elimination of androgenic effect with retained anabolic effect and oral safety remains unachieved.)
Option B: Option B is incorrect; anabolic and androgenic effects are not mediated by two separate receptors — they share the androgen receptor, which is exactly why dissociation is incomplete.
Option C: Option C is incorrect; conferring oral activity on classic steroids has required 17-alpha-alkylation, so its hepatotoxicity is directly relevant, not irrelevant.
Option D: Option D is incorrect; androgenic effects are mediated by the androgen receptor, not the estrogen receptor, so aromatase blockade does not separate anabolic from androgenic activity.
Option E: Option E is incorrect; the hepatotoxicity of 17-alpha-alkylated oral steroids arises from impaired hepatic conjugation and biliary excretion, not from renal metabolism, so bypassing the kidney would not validate the claim.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.